SAMD9 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, WB, E |
---|---|
Primary Accession | Q5K651 |
Other Accession | NP_060124.2 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 184281 Da |
Antigen Region | 1165-1193 aa |
Gene ID | 54809 |
---|---|
Other Names | Sterile alpha motif domain-containing protein 9, SAM domain-containing protein 9, SAMD9, C7orf5, DRIF1, KIAA2004, OEF1 |
Target/Specificity | This SAMD9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1165-1193 amino acids from the C-terminal region of human SAMD9. |
Dilution | WB~~1:1000 IHC-P~~1:50~100 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | SAMD9 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | SAMD9 |
---|---|
Synonyms | C7orf5, DRIF1, KIAA2004, OEF1 |
Function | Double-stranded nucleic acid binding that acts as an antiviral factor by playing an essential role in the formation of cytoplasmic antiviral granules (PubMed:25428864, PubMed:28157624). May play a role in the inflammatory response to tissue injury and the control of extra-osseous calcification, acting as a downstream target of TNF-alpha signaling. Involved in the regulation of EGR1, in coordination with RGL2. May be involved in endosome fusion. |
Cellular Location | Cytoplasm |
Tissue Location | Widely expressed. Very low levels are detected in skeletal muscle. Not detected in brain. Down-regulated in aggressive fibromatosis, as well as in breast and colon cancers. Up-regulated in fibroblasts from patients with normophosphatemic tumoral calcinosis (NFTC). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Tanaka, M., et al. Int. J. Cancer 126(8):1982-1991(2010)
Chefetz, I., et al. J. Invest. Dermatol. 128(6):1423-1429(2008)
Dereure, O. Ann Dermatol Venereol 134 (5 PT 1), 505 (2007) :
Li, C.F., et al. BMC Genomics 8, 92 (2007) :
Topaz, O., et al. Am. J. Hum. Genet. 79(4):759-764(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.